#Italy #Milan #Implantica #RefluxStop #GERD Treatment

Implantica's Innovative Approach to Gastroesophageal Reflux Disease (GERD) Treatment

Implantica AG, a pioneering medtech firm, has recently made headlines with a newly published health economics study demonstrating that its RefluxStop® device offers superior cost-effectiveness in treating gastroesophageal reflux disease (GERD) within the Italian healthcare system. This landmark study, undertaken by the York Health Economics Consortium in collaboration with leading anti-reflux surgeons in Italy, reveals compelling evidence suggesting RefluxStop® can substantially reduce treatment costs for patients suffering from GERD.

What is RefluxStop®?

RefluxStop® is a cutting-edge medical device specifically designed to tackle the root cause of acid reflux without impairing the natural function of the digestive system. Unlike traditional approaches, which involve invasive surgeries that can lead to various side effects, RefluxStop® preserves physiological functions while effectively restoring the lower esophageal sphincter's anatomy. This innovative approach aims to improve patient outcomes and enhance overall quality of life for those plagued by GERD—a condition that affects over a billion individuals globally.

Study Findings: A Game-Changer for Cost-Effectiveness

The findings of the study reveal that RefluxStop® stands out with a 100% probability of being more cost-effective compared to conventional treatments like proton pump inhibitors (PPIs) and magnetic sphincter augmentation (MSA). Additionally, the study shows a 97% probability of being more economically advantageous than the commonly employed Nissen fundoplication surgery. These results strongly position RefluxStop® as a transformative solution in the Italian health system, especially as it gains approval for public funding across various regions in the country.

Dr. Peter Forsell, CEO of Implantica and the inventor of RefluxStop®, emphasized the importance of both clinical effectiveness and cost-efficiency when launching new treatments. He commented, "Italy serves as a prime example where health economics and the efficacy of RefluxStop® intersect beautifully, ensuring its integration into the public healthcare procurement system. We are profoundly appreciative of the independent surgeons who have collaborated to gather and publish this critical data, which drives surgical innovation for GERD patients everywhere."

Implications for Patients and Healthcare Providers

With an estimated 12 million adult GERD sufferers in Italy alone, the implications of this study are monumental. Dr. Forsell expressed optimism for RefluxStop® making a remarkable long-term impact on patients' lives throughout the country. Given the recent withdrawal of Ethicon's magnetic sphincter augmentation device (LINX) from the European market, Implantica is well-prepared to fill that gap, ensuring patients have access to the innovative RefluxStop®.

The results of the study not only highlight the device's clinical and economic advantages but also signify a shift in how GERD is managed in a public health context. As healthcare systems around the world increasingly focus on cost-effectiveness, the findings validate RefluxStop® as a viable option that healthcare providers can offer to patients.

Transforming the Future of GERD Treatment

Implantica remains committed to advancing healthcare technologies to improve patient outcomes. Beyond RefluxStop®, the company is developing additional patent-protected products, including an eHealth platform aimed at enhancing communication and monitoring for implantable devices. This could potentially change treatment paradigms by allowing modifications to be made remotely, thereby saving costs for healthcare systems.

Implantica is publicly listed on the Nasdaq First North Premier Growth Market, furthering its mission to revolutionize the landscape of anti-reflux treatments. The research backing RefluxStop® marks a significant leap forward for both patients and healthcare providers alike, promising to deliver not only clinical success but also cost savings in managing GERD effectively.